litlas
Log inCreate account

David C. Linehan

Active 1995–2025

85
Papers
18,559
Citations
72
h-index
84
i10-index

Citations

Citations per year for David C. Linehan1995: 5 citations1996: 14 citations1997: 11 citations1998: 13 citations1999: 21 citations2000: 32 citations2001: 45 citations2002: 29 citations2003: 34 citations2004: 57 citations2005: 79 citations2006: 111 citations2007: 129 citations2008: 111 citations2009: 114 citations2010: 99 citations2011: 89 citations2012: 119 citations2013: 142 citations2014: 178 citations2015: 179 citations2016: 238 citations2017: 269 citations2018: 213 citations2019: 747 citations2020: 797 citations2021: 906 citations2022: 632 citations2023: 493 citations2024: 800 citations2025: 364 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,470 citing papers, 30.3% of this breakdownChina: 1,191 citing papers, 14.6% of this breakdownUnited Kingdom: 453 citing papers, 5.6% of this breakdownGermany: 432 citing papers, 5.3% of this breakdownItaly: 398 citing papers, 4.9% of this breakdownFrance: 345 citing papers, 4.2% of this breakdownJapan: 334 citing papers, 4.1% of this breakdownNetherlands: 219 citing papers, 2.7% of this breakdownCanada: 185 citing papers, 2.3% of this breakdownAustralia: 176 citing papers, 2.2% of this breakdownSpain: 165 citing papers, 2% of this breakdownSouth Korea: 149 citing papers, 1.8% of this breakdown
0%30.3%Other 20%

Institutions

Fields

  • Medicine55.9%
  • Immunology and Microbiology28.2%
  • Biochemistry, Genetics and Molecular Biology13%
  • Engineering1.2%
  • Neuroscience0.5%
  • Materials Science0.3%
  • Other0.9%

Topics

  • Pancreatic and Hepatic Oncology Research9.4%
  • Immune cells in cancer8.6%
  • Cancer Immunotherapy and Biomarkers8.1%
  • Immunotherapy and Immune Responses5.6%
  • Immune Cell Function and Interaction5%
  • Cancer Genomics and Diagnostics2.9%
  • Other60.4%

Coauthors

All papers

Open in search
  1. CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

    Authors: Yu Zhu, Brett L. Knolhoff, Melissa A. Meyer, Timothy M. Nywening, Brian L. West, Jingqin Luo, Andrea Wang‐Gillam, S. Peter Goedegebuure, David C. Linehan, David G. DeNardo - Cancer Research 2014 cited by 1,287

  2. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

    Authors: Timothy M. Nywening, Andrea Wang‐Gillam, Dominic E. Sanford, Brian A. Belt, Roheena Z. Panni, Brian Cusworth, Adetunji T. Toriola, Rebecca Nieman, Lori A. Worley, Motoyo Yano, Kathryn J. Fowler, A. Craig Lockhart, Rama Suresh, Benjamin Tan, Kian‐Huat Lim, Ryan C. Fields, Steven M. Strasberg, William G. Hawkins, David G. DeNardo, S. Peter Goedegebuure, David C. Linehan - The Lancet Oncology 2016 cited by 778

  3. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

    Authors: Timothy M. Nywening, Brian A. Belt, Darren R. Cullinan, Roheena Z. Panni, Booyeon J. Han, Dominic E. Sanford, Ryan C Jacobs, Jian Ye, Ankit A. Patel, William E. Gillanders, Ryan C. Fields, David G. DeNardo, William G. Hawkins, Peter S. Goedegebuure, David C. Linehan - Gut 2017 cited by 481

  4. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

    Authors: Nicholas A. Ullman, Paul R. Burchard, Richard F. Dunne, David C. Linehan - Journal of Clinical Oncology 2022 cited by 311

  5. Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

    Authors: Jonathan B. Mitchem, Donal J. Brennan, Brett L. Knolhoff, Brian A. Belt, Yu Zhu, Dominic E. Sanford, Larisa Belaygorod, Danielle Carpenter, Lynne Collins, David Piwnica‐Worms, Stephen M. Hewitt, Girish Mallya Udupi, William M. Gallagher, Craig D. Wegner, Brian L. West, Andrea Wang‐Gillam, Peter S. Goedegebuure, David C. Linehan, David G. DeNardo - Cancer Research 2012 cited by 941

  6. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

    Authors: Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, Eric Gamelin, Bishu Ganguly, Donghua Yin, Tenshang Joh, Ira Jacobs, Carrie Turich Taylor, Maeve A. Lowery - Investigational New Drugs 2019 cited by 182

  7. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

    Authors: Dominic E. Sanford, Brian A. Belt, Roheena Z. Panni, Allese Mayer, Anjali D. Deshpande, Danielle Carpenter, Jonathan B. Mitchem, Stacey M. Plambeck-Suess, Lori A. Worley, Brian D. Goetz, Andrea Wang‐Gillam, Timothy J. Eberlein, David G. DeNardo, S. Peter Goedegebuure, David C. Linehan - Clinical Cancer Research 2013 cited by 613

  8. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer

    Authors: Naim U. Rashid, Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, Silvia G. Herrera, Kristin J. Moore, Sarah G. Hennessey, Ashley B. Morrison, Ryan Kawalerski, Apoorve Nayyar, Audrey E. Chang, Benjamin Schmidt, Han Jo Kim, David C. Linehan, Jen Jen Yeh - Clinical Cancer Research 2019 cited by 238

  9. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

    Authors: Hannah L. Williams, Andressa Dias Costa, Jinming Zhang, Srivatsan Raghavan, Peter Winter, Kevin S. Kapner, Scott P. Ginebaugh, Sara A. Väyrynen, Juha P. Väyrynen, Chen Yuan, Andrew W. Navia, Junning Wang, Annan Yang, Timothy L. Bosse, Radha L. Kalekar, Kristen E. Lowder, Mai Chan Lau, Dalia Elganainy, Vicente Morales-Oyarvide, Douglas A. Rubinson, Harshabad Singh, Kimberly Perez, James M. Cleary, Thomas E. Clancy, Jiping Wang, Joseph D. Mancias, Lauren K. Brais, Emma R. Hill, Margaret M. Kozak, David C. Linehan, Richard F. Dunne, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, William C. Hahn, Alex K. Shalek, Andrew J. Aguirre, Jonathan A. Nowak, Brian M. Wolpin - Cancer Research 2022 cited by 90

  10. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    Authors: Mark Sausen, Jillian Phallen, Vilmos Adleff, Siân Jones, Rebecca Leary, Michael T. Barrett, Valsamo Anagnostou, Sonya Parpart-Li, Derek Murphy, Qing Kay Li, Carolyn Hruban, Rob Scharpf, James R. White, Peter J. O’Dwyer, Peter J. Allen, James R. Eshleman, Craig B. Thompson, David S. Klimstra, David C. Linehan, Anirban Maitra, Ralph H. Hruban, Luis A. Díaz, Daniel D. Von Hoff, Julia S. Johansen, Jeffrey A. Drebin, Victor E. Velculescu - Nature Communications 2015 cited by 484

  11. Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

    Authors: Marcus Tan, Peter S. Goedegebuure, Brian A. Belt, Brian Flaherty, Narendra V. Sankpal, William E. Gillanders, Timothy J. Eberlein, Chyi‐Song Hsieh, David C. Linehan - The Journal of Immunology 2009 cited by 450

  12. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer

    Authors: Sara A. Väyrynen, Jinming Zhang, Chen Yuan, Juha P. Väyrynen, Andressa Dias Costa, Hannah L. Williams, Vicente Morales‐Oyarvide, Mai Chan Lau, Douglas A. Rubinson, Richard F. Dunne, Margaret M. Kozak, Wenjia Wang, Diana Agostini‐Vulaj, Michael G. Drage, Lauren K. Brais, Emma Reilly, Osama E. Rahma, Thomas E. Clancy, Jiping Wang, David C. Linehan, Andrew J. Aguirre, Charles S. Fuchs, Lisa M. Coussens, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, Shuji Ogino, Jonathan A. Nowak, Brian M. Wolpin - Clinical Cancer Research 2020 cited by 159

  13. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

    Authors: Zhi Rong Qian, Douglas A. Rubinson, Jonathan A. Nowak, Vicente Morales‐Oyarvide, Richard F. Dunne, Margaret M. Kozak, Marisa W. Welch, Lauren K. Brais, Annacarolina da Silva, Tingting Li, Wanwan Li, Atsuhiro Masuda, Juhong Yang, Yan Shi, Mancang Gu, Yohei Masugi, Justin Bui, Caitlin L. Zellers, Chen Yuan, Ana Babić, Natalia Khalaf, Andrew J. Aguirre, Kimmie Ng, Rebecca A. Miksad, Andrea J. Bullock, Daniel T. Chang, Jennifer F. Tseng, Thomas E. Clancy, David C. Linehan, Jennifer J. Findeis-Hosey, Leona A. Doyle, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Angelica Laing, William C. Hahn, Matthew Meyerson, Charles S. Fuchs, Shuji Ogino, Jason L. Hornick, Aram F. Hezel, Albert C. Koong, Brian M. Wolpin - JAMA Oncology 2017 cited by 269

  14. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance

    Authors: Melissa A. Meyer, John Baer, Brett L. Knolhoff, Timothy M. Nywening, Roheena Z. Panni, Xinming Su, Katherine N. Weilbaecher, William G. Hawkins, X. Cynthia, Ryan C. Fields, David C. Linehan, Grant A. Challen, Roberta Faccio, Rebecca Aft, David G. DeNardo - Nature Communications 2018 cited by 213

  15. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

    Authors: Jian Ye, Bradley N. Mills, Shuyang Qin, Jesse Garrett-Larsen, Joseph D. Murphy, Taylor P. Uccello, Booyeon J. Han, Tara G Vrooman, Carl J. Johnston, Edith M. Lord, Brian A. Belt, David C. Linehan, Scott A. Gerber - Journal for ImmunoTherapy of Cancer 2022 cited by 74

  16. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer

    Authors: Andressa Dias Costa, Sara A. Väyrynen, Akhil Chawla, Jinming Zhang, Juha P. Väyrynen, Mai Chan Lau, Hannah L. Williams, Chen Yuan, Vicente Morales-Oyarvide, Dalia Elganainy, Harshabad Singh, James M. Cleary, Kimberly Perez, Kimmie Ng, William A. Freed-Pastor, Joseph D. Mancias, Stephanie K. Dougan, Jiping Wang, Douglas A. Rubinson, Richard F. Dunne, Margaret M. Kozak, Lauren K. Brais, Emma Reilly, Thomas E. Clancy, David C. Linehan, Daniel T. Chang, Aram F. Hezel, Albert C. Koong, Andrew J. Aguirre, Brian M. Wolpin, Jonathan A. Nowak - Clinical Cancer Research 2022 cited by 76

  17. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma

    Authors: Udaya Liyanage, Todd T. Moore, Hong‐Gu Joo, Yoshiyuki Tanaka, Virginia M. Herrmann, Gerard M. Doherty, Jeffrey A. Drebin, Steven M. Strasberg, Timothy J. Eberlein, Peter S. Goedegebuure, David C. Linehan - The Journal of Immunology 2002 cited by 1,462

  18. Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

    Authors: Mark P. Callery, Kenneth J. Chang, Elliot K. Fishman, Mark S. Talamonti, L. William Traverso, David C. Linehan - Annals of Surgical Oncology 2009 cited by 898

  19. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

    Authors: Matthew R. Porembka, Jonathan B. Mitchem, Brian A. Belt, Chyi‐Song Hsieh, Hyang-Mi Lee, John M. Herndon, William E. Gillanders, David C. Linehan, Peter S. Goedegebuure - Cancer Immunology Immunotherapy 2012 cited by 278

  20. Recruitment of CCR2+tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer

    Authors: Julie Grossman, Timothy M. Nywening, Brian A. Belt, Roheena Z. Panni, Bradley A. Krasnick, David G. DeNardo, William G. Hawkins, S. Peter Goedegebuure, David C. Linehan, Ryan C. Fields - OncoImmunology 2018 cited by 115

  21. The clonal evolution of metastatic colorectal cancer

    Authors: Ha X. Dang, Bradley A. Krasnick, Brian S. White, Julie Grossman, Matthew S. Strand, Jin Zhang, Christopher R. Cabanski, Christopher A. Miller, Robert S. Fulton, S. Peter Goedegebuure, Catrina C. Fronick, Malachi Griffith, David E. Larson, Brian D. Goetz, Jason Walker, William G. Hawkins, Steven M. Strasberg, David C. Linehan, Kian‐Huat Lim, A. Craig Lockhart, Elaine R. Mardis, Richard K. Wilson, Timothy J. Ley, Christopher A. Maher, Ryan C. Fields - Science Advances 2020 cited by 77

  22. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity

    Authors: Luis I. Ruffolo, Katherine M. Jackson, Peyton C. Kuhlers, Benjamin S. Dale, Nathania M Figueroa Guilliani, Nicholas A. Ullman, Paul R. Burchard, Shuyang Qin, Peter Juviler, Jessica M. Keilson, Ashley B. Morrison, Mary Georger, Rachel Jewell, Laura M. Calvi, Timothy M. Nywening, Michael R. O’Dell, Aram F. Hezel, Luis E. De Las Casas, Gregory B. Lesinski, Jen Jen Yeh, Roberto Hernandez‐Alejandro, Brian A. Belt, David C. Linehan - Gut 2021 cited by 74

  23. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy

    Authors: Bradley N. Mills, Haoming Qiu, Michael G. Drage, Chunmo Chen, Jocelyn S. Mathew, Jesse Garrett-Larsen, Jian Ye, Taylor P. Uccello, Joseph D. Murphy, Brian A. Belt, Edith M. Lord, Alan W. Katz, David C. Linehan, Scott A. Gerber - Clinical Cancer Research 2021 cited by 68

  24. The Accordion Severity Grading System of Surgical Complications

    Authors: Steven M. Strasberg, David C. Linehan, William G. Hawkins - Annals of Surgery 2009 cited by 672